{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T18:10:14Z","timestamp":1772993414198,"version":"3.50.1"},"reference-count":69,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surgonc.theclinics.com","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgical Oncology Clinics of North America"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.soc.2023.06.007","type":"journal-article","created":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T09:27:26Z","timestamp":1690882046000},"page":"43-58","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Controversies of Direct-Acting Antivirals in Hepatocellular Carcinoma"],"prefix":"10.1016","volume":"33","author":[{"given":"Ifrah","family":"Fatima","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neehar D.","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alisa","family":"Likhitsup","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.soc.2023.06.007_bib1","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.30297","article-title":"Estimating Prevalence of Hepatitis C Virus Infection in the United States, 2013-2016","volume":"69","author":"Hofmeister","year":"2019","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.soc.2023.06.007_bib2","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jhep.2006.05.013","article-title":"The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide","volume":"45","author":"Perz","year":"2006","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1016\/j.soc.2023.06.007_bib3","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1002\/hep.27969","article-title":"World-wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma","volume":"62","author":"de Martel","year":"2015","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.soc.2023.06.007_bib4","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/apt.13823","article-title":"All-oral direct-acting antiviral therapy in HCV-advanced liver disease is effective in real-world practice: observations through HCV-TARGET database","volume":"45","author":"Reddy","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.soc.2023.06.007_bib5","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/jvh.13232","article-title":"Real-world impact following initiation of interferon-free hepatitis C regimens on liver-related outcomes and all-cause mortality among patients with compensated cirrhosis","volume":"27","author":"McDonald","year":"2020","journal-title":"J\u00a0Viral Hepat"},{"issue":"7","key":"10.1016\/j.soc.2023.06.007_bib6","doi-asserted-by":"crossref","first-page":"e2011055","DOI":"10.1001\/jamanetworkopen.2020.11055","article-title":"Association of Direct-Acting Antiviral Treatment With Mortality Among Medicare Beneficiaries With Hepatitis C","volume":"3","author":"Kaldindi","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.soc.2023.06.007_bib7","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.jhep.2020.03.031","article-title":"DAA therapy and long-term hepatic function in advanced\/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort","volume":"73","author":"Verna","year":"2020","journal-title":"J\u00a0Hepatol"},{"issue":"5","key":"10.1016\/j.soc.2023.06.007_bib8","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/jvh.13482","article-title":"Impact of direct-acting antiviral regimens on mortality and morbidity outcomes in patients with chronic hepatitis c: Systematic review and meta-analysis","volume":"28","author":"Sahakyan","year":"2021","journal-title":"J\u00a0Viral Hepat"},{"issue":"1","key":"10.1016\/j.soc.2023.06.007_bib9","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3390\/v15010137","article-title":"Patients Treated for HCV Infection and Listed for Liver Transplantation in a French Multicenter Study: What Happens at Five Years?","volume":"15","author":"Meunier","year":"2022","journal-title":"Viruses"},{"issue":"2","key":"10.1016\/j.soc.2023.06.007_bib10","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/hep.31060","article-title":"AASLD-IDSA Hepatitis C Guidance Panel. Hepatitis C Guidance 2019\u00a0Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection","volume":"71","author":"Ghany","year":"2020","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.soc.2023.06.007_bib11","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1053\/j.gastro.2019.02.046","article-title":"AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review","volume":"156","author":"Singal","year":"2019","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.soc.2023.06.007_bib12","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.3390\/ijms20061358","article-title":"Molecular Mechanisms Driving Progression of Liver Cirrhosis towards Hepatocellular Carcinoma in Chronic Hepatitis B and C Infections: A Review","volume":"20","author":"Kanda","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.soc.2023.06.007_bib13","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1002\/hep.27222","article-title":"Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go?","volume":"60","author":"El-Serag","year":"2014","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.soc.2023.06.007_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4254\/wjh.v11.i1.1","article-title":"Hepatocellular carcinoma in non-cirrhotic liver: A comprehensive review","volume":"11","author":"Desai","year":"2019","journal-title":"World J Hepatol"},{"key":"10.1016\/j.soc.2023.06.007_bib15","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13027-017-0138-5","article-title":"Frequency and geographic distribution of TERT promoter mutations in primary hepatocellular carcinoma","volume":"12","author":"Pezzuto","year":"2017","journal-title":"Infect Agent Cancer"},{"key":"10.1016\/j.soc.2023.06.007_bib16","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1146\/annurev.pathol.4.110807.092202","article-title":"Tumor suppressors, chromosomal instability, and hepatitis C virus-associated liver cancer","volume":"4","author":"McGivern","year":"2009","journal-title":"Annu Rev Pathol"},{"issue":"4","key":"10.1016\/j.soc.2023.06.007_bib17","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.jhep.2016.06.015","article-title":"Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals","volume":"65","author":"Conti","year":"2016","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1016\/j.soc.2023.06.007_bib18","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1053\/j.gastro.2017.06.012","article-title":"Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents","volume":"153","author":"Kanwal","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.soc.2023.06.007_bib19","article-title":"HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma","author":"Ioannou","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1016\/j.soc.2023.06.007_bib20","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jhep.2016.06.019","article-title":"Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis","volume":"65","author":"Cheung","year":"2016","journal-title":"J\u00a0Hepatol"},{"issue":"6","key":"10.1016\/j.soc.2023.06.007_bib21","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1159\/000450551","article-title":"Liver Fibrosis and Body Mass Index Predict Hepatocarcinogenesis following Eradication of Hepatitis C Virus RNA by Direct-Acting Antivirals","volume":"91","author":"Akuta","year":"2016","journal-title":"Oncology"},{"issue":"4","key":"10.1016\/j.soc.2023.06.007_bib22","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1053\/j.gastro.2016.12.021","article-title":"Unusually High Rates of Hepatocellular Carcinoma After Treatment With Direct-Acting Antiviral Therapy for Hepatitis C Related Cirrhosis","volume":"152","author":"Ravi","year":"2017","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.soc.2023.06.007_bib23","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.jhep.2017.01.028","article-title":"Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort","volume":"66","author":"Calleja","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1016\/j.soc.2023.06.007_bib24","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.jhep.2017.10.033","article-title":"The risk of hepatocellular carcinoma in cirrhotic patients with hepatitis C and sustained viral response: Role of the treatment regimen","volume":"68","author":"Innes","year":"2018","journal-title":"J\u00a0Hepatol"},{"issue":"6","key":"10.1016\/j.soc.2023.06.007_bib25","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1002\/hep.29707","article-title":"The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals: An ERCHIVES study","volume":"67","author":"Li","year":"2018","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.soc.2023.06.007_bib26","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jhep.2018.03.009","article-title":"Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study","volume":"69","author":"Romano","year":"2018","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.soc.2023.06.007_bib27","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1053\/j.gastro.2018.04.008","article-title":"Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents","volume":"155","author":"Calvaruso","year":"2018","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.soc.2023.06.007_bib28","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1111\/jvh.12982","article-title":"Lack of reduction in serum alpha-fetoprotein during treatment with direct antiviral agents predicts hepatocellular carcinoma development in a large cohort of patients with hepatitis C virus-related cirrhosis","volume":"25","author":"Masetti","year":"2018","journal-title":"J\u00a0Viral Hepat"},{"issue":"2","key":"10.1016\/j.soc.2023.06.007_bib29","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.dld.2018.10.014","article-title":"Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals","volume":"51","author":"Lleo","year":"2019","journal-title":"Dig Liver Dis"},{"issue":"5","key":"10.1016\/j.soc.2023.06.007_bib30","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.jhep.2019.01.005","article-title":"Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules","volume":"70","author":"Mari\u00f1o","year":"2019","journal-title":"J\u00a0Hepatol"},{"issue":"7","key":"10.1016\/j.soc.2023.06.007_bib31","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1111\/jvh.13276","article-title":"Incidence of HCC in chronic hepatitis C patients with advanced hepatic fibrosis who achieved SVR following DAAs: A prospective study","volume":"27","author":"Shiha","year":"2020","journal-title":"J\u00a0Viral Hepat"},{"issue":"3","key":"10.1016\/j.soc.2023.06.007_bib32","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.jhep.2020.03.030","article-title":"Undefined\/non-malignant hepatic nodules are associated with early occurrence of HCC in DAA-treated patients with HCV-related cirrhosis","volume":"73","author":"Sangiovanni","year":"2020","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.soc.2023.06.007_bib33","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/hep.30823","article-title":"Long-Term Risk of Hepatocellular Carcinoma in HCV Patients Treated With Direct Acting Antiviral Agents","volume":"71","author":"Kanwal","year":"2020","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.soc.2023.06.007_bib34","doi-asserted-by":"crossref","first-page":"e00337","DOI":"10.14309\/ctg.0000000000000337","article-title":"Prediction of Hepatocellular Carcinoma by Liver Stiffness Measurements Using Magnetic Resonance Elastography After Eradicating Hepatitis C Virus","volume":"12","author":"Kumada","year":"2021","journal-title":"Clin Transl Gastroenterol"},{"issue":"2","key":"10.1016\/j.soc.2023.06.007_bib35","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s00535-021-01845-5","article-title":"Liver-related events after direct-acting antiviral therapy in patients with hepatitis C virus-associated cirrhosis","volume":"57","author":"Tahata","year":"2022","journal-title":"J\u00a0Gastroenterol"},{"issue":"11","key":"10.1016\/j.soc.2023.06.007_bib36","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.14309\/ajg.0000000000001968","article-title":"Longitudinal Associations of Risk Factors and Hepatocellular Carcinoma in Patients With Cured Hepatitis C Virus Infection","volume":"117","author":"Kramer","year":"2022","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.soc.2023.06.007_bib37","doi-asserted-by":"crossref","first-page":"e0262267","DOI":"10.1371\/journal.pone.0262267","article-title":"Features of patients who developed hepatocellular carcinoma after direct-acting antiviral treatment for hepatitis C Virus","volume":"17","author":"Mawatari","year":"2022","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.soc.2023.06.007_bib38","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3390\/v15010221","article-title":"Incidence and Risk Factors of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C Treated with Direct-Acting Antivirals","volume":"15","author":"Leal","year":"2023","journal-title":"Viruses"},{"issue":"4","key":"10.1016\/j.soc.2023.06.007_bib39","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jhep.2016.04.008","article-title":"Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy","volume":"65","author":"Reig","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.soc.2023.06.007_bib40","first-page":"e748","article-title":"Hepatocellular carcinoma in HCV cirrhosis after viral clearance with direct acting antiviral therapy: preliminary evidence and possible meanings","volume":"3","author":"Rinaldi","year":"2016","journal-title":"World Cancer Research Journal"},{"issue":"4","key":"10.1016\/j.soc.2023.06.007_bib41","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.jhep.2016.05.045","volume":"65","year":"2016","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1016\/j.soc.2023.06.007_bib42","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2016.05.034","article-title":"Hepatocellular carcinoma recurrence after treatment with direct-acting antivirals: First, do no harm by withdrawing treatment","volume":"65","author":"Torres","year":"2016","journal-title":"J\u00a0Hepatol"},{"issue":"5","key":"10.1016\/j.soc.2023.06.007_bib43","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.jhep.2016.07.029","article-title":"Unexpected high incidence of hepatocellular carcinoma in patients with hepatitis C in the era of DAAs: Too alarming?","volume":"65","author":"Zeng","year":"2016","journal-title":"J\u00a0Hepatol"},{"issue":"11","key":"10.1016\/j.soc.2023.06.007_bib44","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1111\/jvh.12726","article-title":"The risk of early occurrence and recurrence of hepatocellular carcinoma in hepatitis C-infected patients treated with direct-acting antivirals with and without pegylated interferon: A Belgian experience","volume":"24","author":"Bielen","year":"2017","journal-title":"J\u00a0Viral Hepat"},{"issue":"7","key":"10.1016\/j.soc.2023.06.007_bib45","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/apt.14256","article-title":"Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study","volume":"46","author":"Cabibbo","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"10.1016\/j.soc.2023.06.007_bib46","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1007\/s10620-017-4739-z","article-title":"Direct-Acting Antivirals Decreased Tumor Recurrence After Initial Treatment of Hepatitis C Virus-Related Hepatocellular Carcinoma","volume":"62","author":"Ikeda","year":"2017","journal-title":"Dig Dis Sci"},{"issue":"5","key":"10.1016\/j.soc.2023.06.007_bib47","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.jhep.2017.05.028","article-title":"Effect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C","volume":"67","author":"Nagata","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"8","key":"10.1016\/j.soc.2023.06.007_bib48","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1111\/liv.13456","article-title":"Direct-acting antiviral therapy decreases hepatocellular carcinoma recurrence rate in cirrhotic patients with chronic hepatitis C","volume":"37","author":"Virlogeux","year":"2017","journal-title":"Liver Int"},{"issue":"6","key":"10.1016\/j.soc.2023.06.007_bib49","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/j.jhep.2016.07.043","article-title":"The impact of direct-acting antivirals on early tumor recurrence after radiofrequency ablation in hepatitis C-related hepatocellular carcinoma","volume":"65","author":"Minami","year":"2016","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.soc.2023.06.007_bib50","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jhep.2016.08.016","article-title":"Is the risk of neoplastic recurrence increased after prescribing direct-acting antivirals for HCV patients whose HCC was previously cured?","volume":"66","author":"Zavaglia","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1016\/j.soc.2023.06.007_bib51","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.jhep.2017.07.007","article-title":"Hepatocellular carcinoma recurrence after direct antiviral agent treatment: A European multicentre study","volume":"67","author":"Kolly","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.soc.2023.06.007_bib52","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/hep.29855","article-title":"Direct-acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local-regional therapy or liver transplant waitlist dropout","volume":"68","author":"Huang","year":"2018","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.soc.2023.06.007_bib53","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/jvh.12854","article-title":"Increased recurrence rates of hepatocellular carcinoma after DAA therapy in a hepatitis C-infected Egyptian cohort: A comparative analysis","volume":"25","author":"El Kassas","year":"2018","journal-title":"J\u00a0Viral Hepat"},{"issue":"6","key":"10.1016\/j.soc.2023.06.007_bib54","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.cgh.2018.10.038","article-title":"Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection","volume":"17","author":"Degasperi","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.soc.2023.06.007_bib55","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jhep.2019.03.027","article-title":"Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients","volume":"71","author":"Cabibbo","year":"2019","journal-title":"J\u00a0Hepatol"},{"issue":"5","key":"10.1016\/j.soc.2023.06.007_bib56","doi-asserted-by":"crossref","first-page":"e0233212","DOI":"10.1371\/journal.pone.0233212","article-title":"Impact of direct-acting antiviral therapy for hepatitis C-related hepatocellular carcinoma","volume":"15","author":"Lin","year":"2020","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.soc.2023.06.007_bib57","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s10637-019-00870-9","article-title":"The influence of direct-acting antivirals in hepatitis C virus related hepatocellular carcinoma after curative treatment","volume":"38","author":"Kuo","year":"2020","journal-title":"Invest New Drugs"},{"issue":"3","key":"10.1016\/j.soc.2023.06.007_bib58","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jmii.2019.09.006","article-title":"Direct-acting antivirals for patients with chronic hepatitis C and hepatocellular carcinoma in Taiwan","volume":"54","author":"Chi","year":"2021","journal-title":"J\u00a0Microbiol Immunol Infect"},{"issue":"3","key":"10.1016\/j.soc.2023.06.007_bib59","doi-asserted-by":"crossref","first-page":"410","DOI":"10.5009\/gnl20151","article-title":"Independent Risk Factors for Hepatocellular Carcinoma Recurrence after Direct-Acting Antiviral Therapy in Patients with Chronic Hepatitis C","volume":"15","author":"Ahn","year":"2021","journal-title":"Gut Liver"},{"issue":"1","key":"10.1016\/j.soc.2023.06.007_bib60","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s00535-020-01747-y","article-title":"Direct-acting antivirals improve survival and recurrence rates after treatment of hepatocellular carcinoma within the Milan criteria","volume":"56","author":"Ochi","year":"2021","journal-title":"J\u00a0Gastroenterol"},{"issue":"2","key":"10.1016\/j.soc.2023.06.007_bib61","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1080\/14787210.2021.1951230","article-title":"Impact of successful HCV treatment using direct acting antivirals on recurrence of well ablated hepatocellular carcinoma","volume":"20","author":"Elbaz","year":"2022","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"1","key":"10.1016\/j.soc.2023.06.007_bib62","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/jgh.15659","article-title":"Long-term assessment of recurrence of hepatocellular carcinoma in patients with chronic hepatitis C after viral cure by direct-acting antivirals","volume":"37","author":"Ogawa","year":"2022","journal-title":"J\u00a0Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.soc.2023.06.007_bib63","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1053\/j.gastro.2019.07.040","article-title":"Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma","volume":"157","author":"Singal","year":"2019","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.soc.2023.06.007_bib64","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.jhep.2016.06.023","article-title":"Direct acting antiviral therapy and tumor recurrence after liver transplantation for hepatitis C-associated hepatocellular carcinoma","volume":"65","author":"Yang","year":"2016","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.soc.2023.06.007_bib65","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/apt.14823","article-title":"Systematic review with meta-analysis: recurrence of hepatocellular carcinoma following direct-acting antiviral therapy","volume":"48","author":"Saraiya","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.soc.2023.06.007_bib66","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1136\/gutjnl-2020-323663","article-title":"Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis","volume":"71","author":"Sapena","year":"2022","journal-title":"Gut"},{"issue":"9","key":"10.1016\/j.soc.2023.06.007_bib67","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1111\/jgh.15915","article-title":"Clinical benefits of direct-acting antivirals therapy in hepatitis C virus patients with hepatocellular carcinoma: A systematic review and meta-analysis","volume":"37","author":"Liu","year":"2022","journal-title":"J\u00a0Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.soc.2023.06.007_bib68","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.jhep.2016.07.004","article-title":"Hepatocellular carcinoma and direct acting antiviral treatments: Controversy after the revolution","volume":"65","author":"Nault","year":"2016","journal-title":"J\u00a0Hepatol"},{"issue":"19","key":"10.1016\/j.soc.2023.06.007_bib69","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1002\/cncr.34378","article-title":"Association between sustained virological response and clinical outcomes in patients with hepatitis C infection and hepatocellular carcinoma","volume":"128","author":"Parikh","year":"2022","journal-title":"Cancer"}],"container-title":["Surgical Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1055320723000583?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1055320723000583?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T12:08:19Z","timestamp":1760962099000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1055320723000583"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":69,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S1055320723000583"],"URL":"https:\/\/doi.org\/10.1016\/j.soc.2023.06.007","relation":{},"ISSN":["1055-3207"],"issn-type":[{"value":"1055-3207","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Controversies of Direct-Acting Antivirals in Hepatocellular Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Surgical Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.soc.2023.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}